Clinacin 25 mg Tablets

Pays: Irlande

Langue: anglais

Source: HPRA (Health Products Regulatory Authority)

Ingrédients actifs:

Clindamycin (as clindamycin hydrochloride)

Disponible depuis:

Chanelle Pharmaceuticals Manufacturing Limited

Code ATC:

QJ01FF01

DCI (Dénomination commune internationale):

Clindamycin (as clindamycin hydrochloride)

Dosage:

25 mg/tablet

forme pharmaceutique:

Tablet

Type d'ordonnance:

POM: Prescription Only Medicine as defined in relevant national legislation

Domaine thérapeutique:

clindamycin

Statut de autorisation:

Authorised

Date de l'autorisation:

1999-10-29

Résumé des caractéristiques du produit

Health Products Regulatory Authority
23 April 2019
CRN008R8K
Page 1 of 4
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Clinacin 25 mg Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
Clindamycin 25 mg
(as Clindamycin hydrochloride)
For a full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Tablet. A small round white tablet with a break-line on one side and
the letter J embossed on both sides of the breakline. The
tablets can be divided into equal halves.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs and Cats.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Clinacin 25 mg Tablets are antibiotics indicated for the treatment of
infected wounds, abscesses, pyoderma and oral
cavity/dental infections caused by or associated with
clindamycin-sensitive staphylococci, streptococci, bacteroidaceae,
_Fusobacteriumnecrophorum, Clostridium perfringens_ and osteomyelitis
caused by _Staphylococcus aureus. _Clinacin 25 mg Tablets
can also be used to help provide antimicrobial cover during dental
procedures.
4.3 CONTRAINDICATIONS
Do not use in case of hypersensitivity to clindamycin or lincomycin.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
During prolonged osteomyelitis therapy of one month or greater,
periodic liver and kidney function tests and blood counts
should be performed. Patients with severe renal and/or very severe
hepatic disturbances accompanied by severe metabolic
aberrations should be dosed with caution and should be monitored by
serum examination during high dose clindamycin
therapy.
The product should not be used in cats for longer than 2 weeks as it
may cause liver and gall bladder damage.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY MEDICINAL PRODUCT TO ANIMALS
Wash hands after the administration of the product. Persons with known
hypersensitivity to lincosamides (lincomycin,
clindamycin) should not handle the product.
Health Produ